nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Cyclosporine—systemic lupus erythematosus	0.357	1	CiPCiCtD
Crizotinib—PTK2B—Leflunomide—systemic lupus erythematosus	0.109	0.712	CbGbCtD
Crizotinib—LYN—systemic lupus erythematosus	0.0987	0.319	CbGaD
Crizotinib—LTK—systemic lupus erythematosus	0.0936	0.303	CbGaD
Crizotinib—TYK2—systemic lupus erythematosus	0.0603	0.195	CbGaD
Crizotinib—BLK—systemic lupus erythematosus	0.0567	0.183	CbGaD
Crizotinib—CYP3A5—Dapsone—systemic lupus erythematosus	0.00408	0.0266	CbGbCtD
Crizotinib—CYP3A5—Mycophenolate mofetil—systemic lupus erythematosus	0.00353	0.0231	CbGbCtD
Crizotinib—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.00303	0.0198	CbGbCtD
Crizotinib—CYP3A5—Hydrocortisone—systemic lupus erythematosus	0.00284	0.0185	CbGbCtD
Crizotinib—CYP3A5—Cyclosporine—systemic lupus erythematosus	0.00268	0.0175	CbGbCtD
Crizotinib—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0023	0.015	CbGbCtD
Crizotinib—ABCB1—Betamethasone—systemic lupus erythematosus	0.00197	0.0129	CbGbCtD
Crizotinib—ABCB1—Prednisolone—systemic lupus erythematosus	0.00195	0.0127	CbGbCtD
Crizotinib—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00185	0.0121	CbGbCtD
Crizotinib—ABCB1—Prednisone—systemic lupus erythematosus	0.00184	0.012	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00182	0.0119	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—systemic lupus erythematosus	0.00176	0.0115	CbGbCtD
Crizotinib—ABCB1—Cyclosporine—systemic lupus erythematosus	0.00174	0.0114	CbGbCtD
Crizotinib—CYP3A4—Dapsone—systemic lupus erythematosus	0.00159	0.0104	CbGbCtD
Crizotinib—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00138	0.00901	CbGbCtD
Crizotinib—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00138	0.00901	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00118	0.00773	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00117	0.00763	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00115	0.0075	CbGbCtD
Crizotinib—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00111	0.00723	CbGbCtD
Crizotinib—CYP3A4—Prednisone—systemic lupus erythematosus	0.0011	0.0072	CbGbCtD
Crizotinib—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00104	0.00683	CbGbCtD
Crizotinib—ABCB1—Methotrexate—systemic lupus erythematosus	0.000922	0.00603	CbGbCtD
Crizotinib—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.000688	0.0045	CbGbCtD
Crizotinib—CASK—Mycophenolic acid—Mycophenolate mofetil—systemic lupus erythematosus	0.000453	0.274	CbGdCrCtD
Crizotinib—CDK7—Mycophenolic acid—Mycophenolate mofetil—systemic lupus erythematosus	0.000343	0.208	CbGdCrCtD
Crizotinib—AURKA—Mycophenolic acid—Mycophenolate mofetil—systemic lupus erythematosus	0.000175	0.106	CbGdCrCtD
Crizotinib—CDK7—Sulfathiazole—Dapsone—systemic lupus erythematosus	0.000123	0.0746	CbGdCrCtD
Crizotinib—MAP3K19—lung—systemic lupus erythematosus	0.000115	0.00215	CbGeAlD
Crizotinib—TYK2—cortex of kidney—systemic lupus erythematosus	0.000114	0.00214	CbGeAlD
Crizotinib—MERTK—bone marrow—systemic lupus erythematosus	0.000114	0.00213	CbGeAlD
Crizotinib—MAP3K12—tendon—systemic lupus erythematosus	0.000114	0.00213	CbGeAlD
Crizotinib—ACVR1—tendon—systemic lupus erythematosus	0.000114	0.00213	CbGeAlD
Crizotinib—RPS6KB1—kidney—systemic lupus erythematosus	0.000113	0.00213	CbGeAlD
Crizotinib—JAK2—skin of body—systemic lupus erythematosus	0.000113	0.00212	CbGeAlD
Crizotinib—EPHA6—central nervous system—systemic lupus erythematosus	0.000113	0.00211	CbGeAlD
Crizotinib—JAK3—central nervous system—systemic lupus erythematosus	0.000113	0.00211	CbGeAlD
Crizotinib—IRAK1—cortex of kidney—systemic lupus erythematosus	0.000113	0.00211	CbGeAlD
Crizotinib—TNK2—lung—systemic lupus erythematosus	0.000113	0.00211	CbGeAlD
Crizotinib—IGF1R—lung—systemic lupus erythematosus	0.000113	0.00211	CbGeAlD
Crizotinib—DCLK1—central nervous system—systemic lupus erythematosus	0.000112	0.0021	CbGeAlD
Crizotinib—YES1—connective tissue—systemic lupus erythematosus	0.000111	0.00209	CbGeAlD
Crizotinib—STK35—tendon—systemic lupus erythematosus	0.000111	0.00209	CbGeAlD
Crizotinib—MAP4K2—lung—systemic lupus erythematosus	0.000111	0.00208	CbGeAlD
Crizotinib—NUAK2—bone marrow—systemic lupus erythematosus	0.000111	0.00208	CbGeAlD
Crizotinib—STK4—central nervous system—systemic lupus erythematosus	0.000111	0.00207	CbGeAlD
Crizotinib—RPS6KB1—cortex of kidney—systemic lupus erythematosus	0.00011	0.00207	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—systemic lupus erythematosus	0.00011	0.00206	CbGeAlD
Crizotinib—TAOK3—connective tissue—systemic lupus erythematosus	0.00011	0.00206	CbGeAlD
Crizotinib—ACVR1—bone marrow—systemic lupus erythematosus	0.00011	0.00206	CbGeAlD
Crizotinib—FLT3—bone marrow—systemic lupus erythematosus	0.00011	0.00206	CbGeAlD
Crizotinib—TIE1—lung—systemic lupus erythematosus	0.00011	0.00205	CbGeAlD
Crizotinib—STK3—lung—systemic lupus erythematosus	0.00011	0.00205	CbGeAlD
Crizotinib—AXL—cortex of kidney—systemic lupus erythematosus	0.000109	0.00205	CbGeAlD
Crizotinib—MAP3K3—skin of body—systemic lupus erythematosus	0.000109	0.00204	CbGeAlD
Crizotinib—FER—nervous system—systemic lupus erythematosus	0.000109	0.00204	CbGeAlD
Crizotinib—TYRO3—nervous system—systemic lupus erythematosus	0.000109	0.00204	CbGeAlD
Crizotinib—EPHA5—nervous system—systemic lupus erythematosus	0.000109	0.00204	CbGeAlD
Crizotinib—ALK—nervous system—systemic lupus erythematosus	0.000109	0.00204	CbGeAlD
Crizotinib—ABL2—tendon—systemic lupus erythematosus	0.000108	0.00203	CbGeAlD
Crizotinib—LYN—nervous system—systemic lupus erythematosus	0.000108	0.00203	CbGeAlD
Crizotinib—YES1—nephron tubule—systemic lupus erythematosus	0.000108	0.00202	CbGeAlD
Crizotinib—EPHB4—kidney—systemic lupus erythematosus	0.000107	0.00201	CbGeAlD
Crizotinib—SRC—connective tissue—systemic lupus erythematosus	0.000107	0.00201	CbGeAlD
Crizotinib—BMP2K—tendon—systemic lupus erythematosus	0.000107	0.00201	CbGeAlD
Crizotinib—AURKA—lung—systemic lupus erythematosus	0.000107	0.002	CbGeAlD
Crizotinib—JAK2—kidney—systemic lupus erythematosus	0.000107	0.002	CbGeAlD
Crizotinib—TAOK3—nephron tubule—systemic lupus erythematosus	0.000107	0.002	CbGeAlD
Crizotinib—MAP3K19—nervous system—systemic lupus erythematosus	0.000106	0.00199	CbGeAlD
Crizotinib—BMPR1B—nervous system—systemic lupus erythematosus	0.000106	0.00199	CbGeAlD
Crizotinib—TESK1—lung—systemic lupus erythematosus	0.000106	0.00199	CbGeAlD
Crizotinib—SLK—cortex of kidney—systemic lupus erythematosus	0.000105	0.00197	CbGeAlD
Crizotinib—EPHB4—cortex of kidney—systemic lupus erythematosus	0.000105	0.00196	CbGeAlD
Crizotinib—ALK—central nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—EPHA5—central nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—FER—central nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—TYRO3—central nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—TNK2—nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—IGF1R—nervous system—systemic lupus erythematosus	0.000104	0.00196	CbGeAlD
Crizotinib—EPHB6—skin of body—systemic lupus erythematosus	0.000104	0.00195	CbGeAlD
Crizotinib—LYN—central nervous system—systemic lupus erythematosus	0.000104	0.00195	CbGeAlD
Crizotinib—JAK2—cortex of kidney—systemic lupus erythematosus	0.000104	0.00195	CbGeAlD
Crizotinib—BMP2K—bone marrow—systemic lupus erythematosus	0.000104	0.00195	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—systemic lupus erythematosus	0.000103	0.00194	CbGeAlD
Crizotinib—PTK2B—tendon—systemic lupus erythematosus	0.000103	0.00194	CbGeAlD
Crizotinib—MERTK—lung—systemic lupus erythematosus	0.000103	0.00193	CbGeAlD
Crizotinib—TEK—kidney—systemic lupus erythematosus	0.000103	0.00193	CbGeAlD
Crizotinib—RIPK2—tendon—systemic lupus erythematosus	0.000103	0.00192	CbGeAlD
Crizotinib—MAP3K19—central nervous system—systemic lupus erythematosus	0.000102	0.00192	CbGeAlD
Crizotinib—BMPR1B—central nervous system—systemic lupus erythematosus	0.000102	0.00192	CbGeAlD
Crizotinib—TIE1—nervous system—systemic lupus erythematosus	0.000101	0.0019	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—systemic lupus erythematosus	0.000101	0.0019	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—systemic lupus erythematosus	0.000101	0.0019	CbGeAlD
Crizotinib—LIMK2—lung—systemic lupus erythematosus	0.000101	0.00189	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—systemic lupus erythematosus	0.000101	0.00189	CbGeAlD
Crizotinib—TNK2—central nervous system—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—IGF1R—central nervous system—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—NUAK2—lung—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—PTK2B—bone marrow—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—MAP4K5—cortex of kidney—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—MAP3K3—cortex of kidney—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—TEK—cortex of kidney—systemic lupus erythematosus	0.0001	0.00188	CbGeAlD
Crizotinib—MAP3K12—lung—systemic lupus erythematosus	9.96e-05	0.00187	CbGeAlD
Crizotinib—FLT3—lung—systemic lupus erythematosus	9.96e-05	0.00187	CbGeAlD
Crizotinib—ACVR1—lung—systemic lupus erythematosus	9.96e-05	0.00187	CbGeAlD
Crizotinib—RIPK2—bone marrow—systemic lupus erythematosus	9.93e-05	0.00186	CbGeAlD
Crizotinib—EPHA4—tendon—systemic lupus erythematosus	9.91e-05	0.00186	CbGeAlD
Crizotinib—AURKA—nervous system—systemic lupus erythematosus	9.88e-05	0.00185	CbGeAlD
Crizotinib—TESK1—nervous system—systemic lupus erythematosus	9.8e-05	0.00184	CbGeAlD
Crizotinib—TIE1—central nervous system—systemic lupus erythematosus	9.76e-05	0.00183	CbGeAlD
Crizotinib—STK35—lung—systemic lupus erythematosus	9.76e-05	0.00183	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—systemic lupus erythematosus	9.74e-05	0.00183	CbGeAlD
Crizotinib—FGR—lymphoid tissue—systemic lupus erythematosus	9.68e-05	0.00182	CbGeAlD
Crizotinib—SRC—skin of body—systemic lupus erythematosus	9.68e-05	0.00182	CbGeAlD
Crizotinib—AXL—lymphoid tissue—systemic lupus erythematosus	9.65e-05	0.00181	CbGeAlD
Crizotinib—CSF1R—connective tissue—systemic lupus erythematosus	9.62e-05	0.00181	CbGeAlD
Crizotinib—EPHB6—cortex of kidney—systemic lupus erythematosus	9.56e-05	0.00179	CbGeAlD
Crizotinib—MERTK—nervous system—systemic lupus erythematosus	9.54e-05	0.00179	CbGeAlD
Crizotinib—PTK2—tendon—systemic lupus erythematosus	9.52e-05	0.00179	CbGeAlD
Crizotinib—TBK1—tendon—systemic lupus erythematosus	9.52e-05	0.00179	CbGeAlD
Crizotinib—AURKA—central nervous system—systemic lupus erythematosus	9.52e-05	0.00179	CbGeAlD
Crizotinib—ABL2—lung—systemic lupus erythematosus	9.51e-05	0.00178	CbGeAlD
Crizotinib—YES1—kidney—systemic lupus erythematosus	9.49e-05	0.00178	CbGeAlD
Crizotinib—TYK2—tendon—systemic lupus erythematosus	9.46e-05	0.00177	CbGeAlD
Crizotinib—TESK1—central nervous system—systemic lupus erythematosus	9.44e-05	0.00177	CbGeAlD
Crizotinib—MAP3K2—bone marrow—systemic lupus erythematosus	9.42e-05	0.00177	CbGeAlD
Crizotinib—STK10—kidney—systemic lupus erythematosus	9.4e-05	0.00176	CbGeAlD
Crizotinib—BMP2K—lung—systemic lupus erythematosus	9.4e-05	0.00176	CbGeAlD
Crizotinib—TAOK3—kidney—systemic lupus erythematosus	9.36e-05	0.00176	CbGeAlD
Crizotinib—IRAK1—tendon—systemic lupus erythematosus	9.33e-05	0.00175	CbGeAlD
Crizotinib—LIMK2—nervous system—systemic lupus erythematosus	9.33e-05	0.00175	CbGeAlD
Crizotinib—YES1—cortex of kidney—systemic lupus erythematosus	9.24e-05	0.00173	CbGeAlD
Crizotinib—MAP3K12—nervous system—systemic lupus erythematosus	9.23e-05	0.00173	CbGeAlD
Crizotinib—ACVR1—nervous system—systemic lupus erythematosus	9.23e-05	0.00173	CbGeAlD
Crizotinib—TBK1—bone marrow—systemic lupus erythematosus	9.22e-05	0.00173	CbGeAlD
Crizotinib—MERTK—central nervous system—systemic lupus erythematosus	9.18e-05	0.00172	CbGeAlD
Crizotinib—TYK2—bone marrow—systemic lupus erythematosus	9.16e-05	0.00172	CbGeAlD
Crizotinib—RPS6KB1—tendon—systemic lupus erythematosus	9.16e-05	0.00172	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—systemic lupus erythematosus	9.15e-05	0.00172	CbGeAlD
Crizotinib—SRC—kidney—systemic lupus erythematosus	9.13e-05	0.00171	CbGeAlD
Crizotinib—TAOK3—cortex of kidney—systemic lupus erythematosus	9.12e-05	0.00171	CbGeAlD
Crizotinib—FGR—tendon—systemic lupus erythematosus	9.1e-05	0.00171	CbGeAlD
Crizotinib—PTK2B—lung—systemic lupus erythematosus	9.08e-05	0.0017	CbGeAlD
Crizotinib—AXL—tendon—systemic lupus erythematosus	9.07e-05	0.0017	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—systemic lupus erythematosus	9.04e-05	0.0017	CbGeAlD
Crizotinib—IRAK1—bone marrow—systemic lupus erythematosus	9.04e-05	0.0017	CbGeAlD
Crizotinib—STK35—nervous system—systemic lupus erythematosus	9.04e-05	0.0017	CbGeAlD
Crizotinib—RIPK2—lung—systemic lupus erythematosus	9e-05	0.00169	CbGeAlD
Crizotinib—LIMK2—central nervous system—systemic lupus erythematosus	8.98e-05	0.00168	CbGeAlD
Crizotinib—MAP3K12—central nervous system—systemic lupus erythematosus	8.88e-05	0.00167	CbGeAlD
Crizotinib—ACVR1—central nervous system—systemic lupus erythematosus	8.88e-05	0.00167	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—systemic lupus erythematosus	8.87e-05	0.00166	CbGeAlD
Crizotinib—TEK—lymphoid tissue—systemic lupus erythematosus	8.82e-05	0.00165	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—systemic lupus erythematosus	8.82e-05	0.00165	CbGeAlD
Crizotinib—FGR—bone marrow—systemic lupus erythematosus	8.82e-05	0.00165	CbGeAlD
Crizotinib—LCK—bone marrow—systemic lupus erythematosus	8.82e-05	0.00165	CbGeAlD
Crizotinib—SLK—tendon—systemic lupus erythematosus	8.73e-05	0.00164	CbGeAlD
Crizotinib—STK35—central nervous system—systemic lupus erythematosus	8.7e-05	0.00163	CbGeAlD
Crizotinib—BMP2K—nervous system—systemic lupus erythematosus	8.7e-05	0.00163	CbGeAlD
Crizotinib—EPHA4—lung—systemic lupus erythematosus	8.7e-05	0.00163	CbGeAlD
Crizotinib—CSF1R—skin of body—systemic lupus erythematosus	8.69e-05	0.00163	CbGeAlD
Crizotinib—EPHB4—tendon—systemic lupus erythematosus	8.67e-05	0.00163	CbGeAlD
Crizotinib—JAK2—tendon—systemic lupus erythematosus	8.6e-05	0.00161	CbGeAlD
Crizotinib—MAP3K2—lung—systemic lupus erythematosus	8.53e-05	0.0016	CbGeAlD
Crizotinib—EPHA2—tendon—systemic lupus erythematosus	8.5e-05	0.00159	CbGeAlD
Crizotinib—SLK—bone marrow—systemic lupus erythematosus	8.45e-05	0.00159	CbGeAlD
Crizotinib—PTK2B—nervous system—systemic lupus erythematosus	8.4e-05	0.00158	CbGeAlD
Crizotinib—EPHB4—bone marrow—systemic lupus erythematosus	8.39e-05	0.00157	CbGeAlD
Crizotinib—BMP2K—central nervous system—systemic lupus erythematosus	8.38e-05	0.00157	CbGeAlD
Crizotinib—CYP3A5—blood plasma—systemic lupus erythematosus	8.36e-05	0.00157	CbGeAlD
Crizotinib—TBK1—lung—systemic lupus erythematosus	8.36e-05	0.00157	CbGeAlD
Crizotinib—PTK2—lung—systemic lupus erythematosus	8.36e-05	0.00157	CbGeAlD
Crizotinib—JAK2—bone marrow—systemic lupus erythematosus	8.33e-05	0.00156	CbGeAlD
Crizotinib—TYK2—lung—systemic lupus erythematosus	8.3e-05	0.00156	CbGeAlD
Crizotinib—MAP3K3—tendon—systemic lupus erythematosus	8.29e-05	0.00156	CbGeAlD
Crizotinib—TEK—tendon—systemic lupus erythematosus	8.29e-05	0.00156	CbGeAlD
Crizotinib—MAP4K5—tendon—systemic lupus erythematosus	8.29e-05	0.00156	CbGeAlD
Crizotinib—IRAK1—lung—systemic lupus erythematosus	8.19e-05	0.00154	CbGeAlD
Crizotinib—YES1—lymphoid tissue—systemic lupus erythematosus	8.15e-05	0.00153	CbGeAlD
Crizotinib—PTK2B—central nervous system—systemic lupus erythematosus	8.09e-05	0.00152	CbGeAlD
Crizotinib—STK10—lymphoid tissue—systemic lupus erythematosus	8.07e-05	0.00151	CbGeAlD
Crizotinib—EPHA4—nervous system—systemic lupus erythematosus	8.06e-05	0.00151	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—systemic lupus erythematosus	8.04e-05	0.00151	CbGeAlD
Crizotinib—RPS6KB1—lung—systemic lupus erythematosus	8.04e-05	0.00151	CbGeAlD
Crizotinib—MAP3K3—bone marrow—systemic lupus erythematosus	8.03e-05	0.00151	CbGeAlD
Crizotinib—MAP4K5—bone marrow—systemic lupus erythematosus	8.03e-05	0.00151	CbGeAlD
Crizotinib—LCK—lung—systemic lupus erythematosus	7.99e-05	0.0015	CbGeAlD
Crizotinib—FGR—lung—systemic lupus erythematosus	7.99e-05	0.0015	CbGeAlD
Crizotinib—AXL—lung—systemic lupus erythematosus	7.96e-05	0.00149	CbGeAlD
Crizotinib—EPHB6—tendon—systemic lupus erythematosus	7.93e-05	0.00149	CbGeAlD
Crizotinib—MAP3K2—nervous system—systemic lupus erythematosus	7.9e-05	0.00148	CbGeAlD
Crizotinib—SRC—lymphoid tissue—systemic lupus erythematosus	7.84e-05	0.00147	CbGeAlD
Crizotinib—EPHA4—central nervous system—systemic lupus erythematosus	7.76e-05	0.00146	CbGeAlD
Crizotinib—PTK2—nervous system—systemic lupus erythematosus	7.74e-05	0.00145	CbGeAlD
Crizotinib—TBK1—nervous system—systemic lupus erythematosus	7.74e-05	0.00145	CbGeAlD
Crizotinib—TYK2—nervous system—systemic lupus erythematosus	7.69e-05	0.00144	CbGeAlD
Crizotinib—SLK—lung—systemic lupus erythematosus	7.66e-05	0.00144	CbGeAlD
Crizotinib—YES1—tendon—systemic lupus erythematosus	7.66e-05	0.00144	CbGeAlD
Crizotinib—ABL1—connective tissue—systemic lupus erythematosus	7.61e-05	0.00143	CbGeAlD
Crizotinib—MAP3K2—central nervous system—systemic lupus erythematosus	7.61e-05	0.00143	CbGeAlD
Crizotinib—EPHB4—lung—systemic lupus erythematosus	7.6e-05	0.00143	CbGeAlD
Crizotinib—STK10—tendon—systemic lupus erythematosus	7.59e-05	0.00142	CbGeAlD
Crizotinib—TAOK3—tendon—systemic lupus erythematosus	7.56e-05	0.00142	CbGeAlD
Crizotinib—JAK2—lung—systemic lupus erythematosus	7.55e-05	0.00142	CbGeAlD
Crizotinib—EPHA2—lung—systemic lupus erythematosus	7.46e-05	0.0014	CbGeAlD
Crizotinib—TBK1—central nervous system—systemic lupus erythematosus	7.45e-05	0.0014	CbGeAlD
Crizotinib—PTK2—central nervous system—systemic lupus erythematosus	7.45e-05	0.0014	CbGeAlD
Crizotinib—RPS6KB1—nervous system—systemic lupus erythematosus	7.44e-05	0.0014	CbGeAlD
Crizotinib—YES1—bone marrow—systemic lupus erythematosus	7.42e-05	0.00139	CbGeAlD
Crizotinib—TYK2—central nervous system—systemic lupus erythematosus	7.4e-05	0.00139	CbGeAlD
Crizotinib—FGR—nervous system—systemic lupus erythematosus	7.4e-05	0.00139	CbGeAlD
Crizotinib—ABL1—nephron tubule—systemic lupus erythematosus	7.37e-05	0.00138	CbGeAlD
Crizotinib—AXL—nervous system—systemic lupus erythematosus	7.37e-05	0.00138	CbGeAlD
Crizotinib—STK10—bone marrow—systemic lupus erythematosus	7.35e-05	0.00138	CbGeAlD
Crizotinib—TAOK3—bone marrow—systemic lupus erythematosus	7.32e-05	0.00137	CbGeAlD
Crizotinib—MAP4K5—lung—systemic lupus erythematosus	7.28e-05	0.00137	CbGeAlD
Crizotinib—MAP3K3—lung—systemic lupus erythematosus	7.28e-05	0.00137	CbGeAlD
Crizotinib—TEK—lung—systemic lupus erythematosus	7.28e-05	0.00137	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—systemic lupus erythematosus	7.17e-05	0.00134	CbGeAlD
Crizotinib—FGR—central nervous system—systemic lupus erythematosus	7.12e-05	0.00134	CbGeAlD
Crizotinib—AXL—central nervous system—systemic lupus erythematosus	7.09e-05	0.00133	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—systemic lupus erythematosus	7.04e-05	0.00132	CbGeAlD
Crizotinib—JAK2—nervous system—systemic lupus erythematosus	6.99e-05	0.00131	CbGeAlD
Crizotinib—EPHB6—lung—systemic lupus erythematosus	6.96e-05	0.0013	CbGeAlD
Crizotinib—EPHA2—nervous system—systemic lupus erythematosus	6.91e-05	0.0013	CbGeAlD
Crizotinib—ABL1—skin of body—systemic lupus erythematosus	6.87e-05	0.00129	CbGeAlD
Crizotinib—Visual impairment—Methylprednisolone—systemic lupus erythematosus	6.82e-05	0.00172	CcSEcCtD
Crizotinib—Anaemia—Cyclosporine—systemic lupus erythematosus	6.82e-05	0.00172	CcSEcCtD
Crizotinib—Decreased appetite—Leflunomide—systemic lupus erythematosus	6.78e-05	0.00171	CcSEcCtD
Crizotinib—MAP4K5—nervous system—systemic lupus erythematosus	6.74e-05	0.00126	CbGeAlD
Crizotinib—MAP3K3—nervous system—systemic lupus erythematosus	6.74e-05	0.00126	CbGeAlD
Crizotinib—TEK—nervous system—systemic lupus erythematosus	6.74e-05	0.00126	CbGeAlD
Crizotinib—JAK2—central nervous system—systemic lupus erythematosus	6.73e-05	0.00126	CbGeAlD
Crizotinib—Gastrointestinal disorder—Leflunomide—systemic lupus erythematosus	6.73e-05	0.0017	CcSEcCtD
Crizotinib—Arrhythmia—Hydrocortisone—systemic lupus erythematosus	6.73e-05	0.0017	CcSEcCtD
Crizotinib—Fatigue—Leflunomide—systemic lupus erythematosus	6.72e-05	0.0017	CcSEcCtD
Crizotinib—YES1—lung—systemic lupus erythematosus	6.72e-05	0.00126	CbGeAlD
Crizotinib—Constipation—Leflunomide—systemic lupus erythematosus	6.67e-05	0.00169	CcSEcCtD
Crizotinib—STK10—lung—systemic lupus erythematosus	6.66e-05	0.00125	CbGeAlD
Crizotinib—EPHA2—central nervous system—systemic lupus erythematosus	6.65e-05	0.00125	CbGeAlD
Crizotinib—Anaemia—Mycophenolate mofetil—systemic lupus erythematosus	6.65e-05	0.00168	CcSEcCtD
Crizotinib—TAOK3—lung—systemic lupus erythematosus	6.64e-05	0.00124	CbGeAlD
Crizotinib—CSF1R—tendon—systemic lupus erythematosus	6.62e-05	0.00124	CbGeAlD
Crizotinib—Eye disorder—Methylprednisolone—systemic lupus erythematosus	6.61e-05	0.00167	CcSEcCtD
Crizotinib—Leukopenia—Cyclosporine—systemic lupus erythematosus	6.6e-05	0.00167	CcSEcCtD
Crizotinib—Cardiac disorder—Methylprednisolone—systemic lupus erythematosus	6.56e-05	0.00166	CcSEcCtD
Crizotinib—Malnutrition—Hydrocortisone—systemic lupus erythematosus	6.55e-05	0.00166	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—systemic lupus erythematosus	6.55e-05	0.00166	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—systemic lupus erythematosus	6.55e-05	0.00166	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—systemic lupus erythematosus	6.54e-05	0.00165	CcSEcCtD
Crizotinib—Body temperature increased—Azathioprine—systemic lupus erythematosus	6.53e-05	0.00165	CcSEcCtD
Crizotinib—TEK—central nervous system—systemic lupus erythematosus	6.49e-05	0.00122	CbGeAlD
Crizotinib—MAP4K5—central nervous system—systemic lupus erythematosus	6.49e-05	0.00122	CbGeAlD
Crizotinib—MAP3K3—central nervous system—systemic lupus erythematosus	6.49e-05	0.00122	CbGeAlD
Crizotinib—ABL1—kidney—systemic lupus erythematosus	6.48e-05	0.00121	CbGeAlD
Crizotinib—SRC—lung—systemic lupus erythematosus	6.47e-05	0.00121	CbGeAlD
Crizotinib—Syncope—Mycophenolate mofetil—systemic lupus erythematosus	6.45e-05	0.00163	CcSEcCtD
Crizotinib—EPHB6—nervous system—systemic lupus erythematosus	6.44e-05	0.00121	CbGeAlD
Crizotinib—Leukopenia—Mycophenolate mofetil—systemic lupus erythematosus	6.44e-05	0.00163	CcSEcCtD
Crizotinib—CSF1R—bone marrow—systemic lupus erythematosus	6.41e-05	0.0012	CbGeAlD
Crizotinib—Mediastinal disorder—Methylprednisolone—systemic lupus erythematosus	6.37e-05	0.00161	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—systemic lupus erythematosus	6.33e-05	0.0016	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—systemic lupus erythematosus	6.33e-05	0.0016	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—systemic lupus erythematosus	6.32e-05	0.0016	CcSEcCtD
Crizotinib—Loss of consciousness—Mycophenolate mofetil—systemic lupus erythematosus	6.32e-05	0.0016	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—systemic lupus erythematosus	6.32e-05	0.0016	CcSEcCtD
Crizotinib—ABL1—cortex of kidney—systemic lupus erythematosus	6.31e-05	0.00118	CbGeAlD
Crizotinib—CYP3A4—blood plasma—systemic lupus erythematosus	6.28e-05	0.00118	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—systemic lupus erythematosus	6.23e-05	0.00158	CcSEcCtD
Crizotinib—YES1—nervous system—systemic lupus erythematosus	6.22e-05	0.00117	CbGeAlD
Crizotinib—EPHB6—central nervous system—systemic lupus erythematosus	6.2e-05	0.00116	CbGeAlD
Crizotinib—Visual impairment—Dexamethasone—systemic lupus erythematosus	6.2e-05	0.00157	CcSEcCtD
Crizotinib—Visual impairment—Betamethasone—systemic lupus erythematosus	6.2e-05	0.00157	CcSEcCtD
Crizotinib—STK10—nervous system—systemic lupus erythematosus	6.17e-05	0.00116	CbGeAlD
Crizotinib—Body temperature increased—Leflunomide—systemic lupus erythematosus	6.16e-05	0.00156	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—systemic lupus erythematosus	6.16e-05	0.00156	CcSEcCtD
Crizotinib—TAOK3—nervous system—systemic lupus erythematosus	6.14e-05	0.00115	CbGeAlD
Crizotinib—Neuropathy peripheral—Prednisone—systemic lupus erythematosus	6.12e-05	0.00155	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic lupus erythematosus	6.08e-05	0.00154	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—systemic lupus erythematosus	6.04e-05	0.00153	CcSEcCtD
Crizotinib—Oedema—Cyclosporine—systemic lupus erythematosus	6.02e-05	0.00152	CcSEcCtD
Crizotinib—Syncope—Prednisolone—systemic lupus erythematosus	6.02e-05	0.00152	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—systemic lupus erythematosus	6.01e-05	0.00152	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—systemic lupus erythematosus	6.01e-05	0.00152	CcSEcCtD
Crizotinib—YES1—central nervous system—systemic lupus erythematosus	5.99e-05	0.00112	CbGeAlD
Crizotinib—SRC—nervous system—systemic lupus erythematosus	5.99e-05	0.00112	CbGeAlD
Crizotinib—Infection—Cyclosporine—systemic lupus erythematosus	5.98e-05	0.00151	CcSEcCtD
Crizotinib—STK10—central nervous system—systemic lupus erythematosus	5.94e-05	0.00111	CbGeAlD
Crizotinib—TAOK3—central nervous system—systemic lupus erythematosus	5.92e-05	0.00111	CbGeAlD
Crizotinib—Nervous system disorder—Cyclosporine—systemic lupus erythematosus	5.9e-05	0.00149	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—systemic lupus erythematosus	5.9e-05	0.00149	CcSEcCtD
Crizotinib—Syncope—Hydrocortisone—systemic lupus erythematosus	5.88e-05	0.00149	CcSEcCtD
Crizotinib—Oedema—Mycophenolate mofetil—systemic lupus erythematosus	5.87e-05	0.00148	CcSEcCtD
Crizotinib—Skin disorder—Cyclosporine—systemic lupus erythematosus	5.85e-05	0.00148	CcSEcCtD
Crizotinib—Infection—Mycophenolate mofetil—systemic lupus erythematosus	5.83e-05	0.00147	CcSEcCtD
Crizotinib—CSF1R—lung—systemic lupus erythematosus	5.81e-05	0.00109	CbGeAlD
Crizotinib—Shock—Mycophenolate mofetil—systemic lupus erythematosus	5.78e-05	0.00146	CcSEcCtD
Crizotinib—SRC—central nervous system—systemic lupus erythematosus	5.77e-05	0.00108	CbGeAlD
Crizotinib—Loss of consciousness—Hydrocortisone—systemic lupus erythematosus	5.76e-05	0.00146	CcSEcCtD
Crizotinib—Nervous system disorder—Mycophenolate mofetil—systemic lupus erythematosus	5.76e-05	0.00146	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—systemic lupus erythematosus	5.75e-05	0.00145	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—systemic lupus erythematosus	5.75e-05	0.00145	CcSEcCtD
Crizotinib—Skin disorder—Mycophenolate mofetil—systemic lupus erythematosus	5.7e-05	0.00144	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—systemic lupus erythematosus	5.7e-05	0.00144	CcSEcCtD
Crizotinib—Diarrhoea—Azathioprine—systemic lupus erythematosus	5.65e-05	0.00143	CcSEcCtD
Crizotinib—Asthenia—Leflunomide—systemic lupus erythematosus	5.59e-05	0.00141	CcSEcCtD
Crizotinib—ABL1—lymphoid tissue—systemic lupus erythematosus	5.56e-05	0.00104	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—systemic lupus erythematosus	5.54e-05	0.0014	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—systemic lupus erythematosus	5.53e-05	0.0014	CcSEcCtD
Crizotinib—Syncope—Methylprednisolone—systemic lupus erythematosus	5.52e-05	0.0014	CcSEcCtD
Crizotinib—Oedema—Prednisolone—systemic lupus erythematosus	5.48e-05	0.00138	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—systemic lupus erythematosus	5.47e-05	0.00138	CcSEcCtD
Crizotinib—Dizziness—Azathioprine—systemic lupus erythematosus	5.46e-05	0.00138	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—systemic lupus erythematosus	5.44e-05	0.00137	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—systemic lupus erythematosus	5.42e-05	0.00137	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—systemic lupus erythematosus	5.41e-05	0.00137	CcSEcCtD
Crizotinib—Paraesthesia—Cyclosporine—systemic lupus erythematosus	5.4e-05	0.00137	CcSEcCtD
Crizotinib—Shock—Prednisolone—systemic lupus erythematosus	5.39e-05	0.00136	CcSEcCtD
Crizotinib—CSF1R—nervous system—systemic lupus erythematosus	5.38e-05	0.00101	CbGeAlD
Crizotinib—Dyspnoea—Cyclosporine—systemic lupus erythematosus	5.37e-05	0.00136	CcSEcCtD
Crizotinib—Oedema—Hydrocortisone—systemic lupus erythematosus	5.35e-05	0.00135	CcSEcCtD
Crizotinib—Diarrhoea—Leflunomide—systemic lupus erythematosus	5.34e-05	0.00135	CcSEcCtD
Crizotinib—Infection—Hydrocortisone—systemic lupus erythematosus	5.31e-05	0.00134	CcSEcCtD
Crizotinib—Dyspepsia—Cyclosporine—systemic lupus erythematosus	5.3e-05	0.00134	CcSEcCtD
Crizotinib—Paraesthesia—Mycophenolate mofetil—systemic lupus erythematosus	5.27e-05	0.00133	CcSEcCtD
Crizotinib—Shock—Hydrocortisone—systemic lupus erythematosus	5.26e-05	0.00133	CcSEcCtD
Crizotinib—Vomiting—Azathioprine—systemic lupus erythematosus	5.25e-05	0.00133	CcSEcCtD
Crizotinib—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	5.25e-05	0.00133	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—systemic lupus erythematosus	5.24e-05	0.00133	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—systemic lupus erythematosus	5.23e-05	0.00132	CcSEcCtD
Crizotinib—Dyspnoea—Mycophenolate mofetil—systemic lupus erythematosus	5.23e-05	0.00132	CcSEcCtD
Crizotinib—Decreased appetite—Cyclosporine—systemic lupus erythematosus	5.23e-05	0.00132	CcSEcCtD
Crizotinib—ABL1—tendon—systemic lupus erythematosus	5.23e-05	0.000981	CbGeAlD
Crizotinib—Infestation NOS—Methotrexate—systemic lupus erythematosus	5.21e-05	0.00132	CcSEcCtD
Crizotinib—Infestation—Methotrexate—systemic lupus erythematosus	5.21e-05	0.00132	CcSEcCtD
Crizotinib—Rash—Azathioprine—systemic lupus erythematosus	5.21e-05	0.00132	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	5.21e-05	0.00132	CcSEcCtD
Crizotinib—Dermatitis—Azathioprine—systemic lupus erythematosus	5.2e-05	0.00132	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	5.2e-05	0.00131	CcSEcCtD
Crizotinib—Skin disorder—Hydrocortisone—systemic lupus erythematosus	5.2e-05	0.00131	CcSEcCtD
Crizotinib—Fatigue—Cyclosporine—systemic lupus erythematosus	5.19e-05	0.00131	CcSEcCtD
Crizotinib—CSF1R—central nervous system—systemic lupus erythematosus	5.18e-05	0.000971	CbGeAlD
Crizotinib—Dyspepsia—Mycophenolate mofetil—systemic lupus erythematosus	5.17e-05	0.00131	CcSEcCtD
Crizotinib—Dizziness—Leflunomide—systemic lupus erythematosus	5.16e-05	0.0013	CcSEcCtD
Crizotinib—Constipation—Cyclosporine—systemic lupus erythematosus	5.15e-05	0.0013	CcSEcCtD
Crizotinib—Decreased appetite—Mycophenolate mofetil—systemic lupus erythematosus	5.1e-05	0.00129	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	5.07e-05	0.00128	CcSEcCtD
Crizotinib—ABL1—bone marrow—systemic lupus erythematosus	5.07e-05	0.00095	CbGeAlD
Crizotinib—Oedema—Triamcinolone—systemic lupus erythematosus	5.04e-05	0.00127	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—systemic lupus erythematosus	5.02e-05	0.00127	CcSEcCtD
Crizotinib—Syncope—Betamethasone—systemic lupus erythematosus	5.02e-05	0.00127	CcSEcCtD
Crizotinib—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	5.02e-05	0.00127	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—systemic lupus erythematosus	5e-05	0.00127	CcSEcCtD
Crizotinib—Infection—Triamcinolone—systemic lupus erythematosus	5e-05	0.00127	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—systemic lupus erythematosus	4.99e-05	0.00126	CcSEcCtD
Crizotinib—Vomiting—Leflunomide—systemic lupus erythematosus	4.96e-05	0.00125	CcSEcCtD
Crizotinib—Shock—Triamcinolone—systemic lupus erythematosus	4.95e-05	0.00125	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—systemic lupus erythematosus	4.94e-05	0.00125	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—systemic lupus erythematosus	4.93e-05	0.00125	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	4.93e-05	0.00125	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	4.92e-05	0.00124	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—systemic lupus erythematosus	4.92e-05	0.00124	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—systemic lupus erythematosus	4.92e-05	0.00124	CcSEcCtD
Crizotinib—Rash—Leflunomide—systemic lupus erythematosus	4.92e-05	0.00124	CcSEcCtD
Crizotinib—Dermatitis—Leflunomide—systemic lupus erythematosus	4.91e-05	0.00124	CcSEcCtD
Crizotinib—Nausea—Azathioprine—systemic lupus erythematosus	4.9e-05	0.00124	CcSEcCtD
Crizotinib—Skin disorder—Methylprednisolone—systemic lupus erythematosus	4.88e-05	0.00123	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—systemic lupus erythematosus	4.88e-05	0.00123	CcSEcCtD
Crizotinib—Paraesthesia—Hydrocortisone—systemic lupus erythematosus	4.8e-05	0.00121	CcSEcCtD
Crizotinib—Body temperature increased—Cyclosporine—systemic lupus erythematosus	4.76e-05	0.0012	CcSEcCtD
Crizotinib—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	4.71e-05	0.00119	CcSEcCtD
Crizotinib—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	4.65e-05	0.00118	CcSEcCtD
Crizotinib—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	4.64e-05	0.00117	CcSEcCtD
Crizotinib—Nausea—Leflunomide—systemic lupus erythematosus	4.63e-05	0.00117	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	4.62e-05	0.00117	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	4.62e-05	0.00117	CcSEcCtD
Crizotinib—Fatigue—Hydrocortisone—systemic lupus erythematosus	4.61e-05	0.00117	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—systemic lupus erythematosus	4.6e-05	0.00116	CcSEcCtD
Crizotinib—ABL1—lung—systemic lupus erythematosus	4.59e-05	0.000861	CbGeAlD
Crizotinib—Urethral disorder—Methotrexate—systemic lupus erythematosus	4.59e-05	0.00116	CcSEcCtD
Crizotinib—Oedema—Betamethasone—systemic lupus erythematosus	4.57e-05	0.00116	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—systemic lupus erythematosus	4.57e-05	0.00116	CcSEcCtD
Crizotinib—Infection—Dexamethasone—systemic lupus erythematosus	4.54e-05	0.00115	CcSEcCtD
Crizotinib—Infection—Betamethasone—systemic lupus erythematosus	4.54e-05	0.00115	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—systemic lupus erythematosus	4.52e-05	0.00114	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	4.51e-05	0.00114	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—systemic lupus erythematosus	4.51e-05	0.00114	CcSEcCtD
Crizotinib—Anaemia—Prednisone—systemic lupus erythematosus	4.51e-05	0.00114	CcSEcCtD
Crizotinib—Shock—Betamethasone—systemic lupus erythematosus	4.5e-05	0.00114	CcSEcCtD
Crizotinib—Shock—Dexamethasone—systemic lupus erythematosus	4.5e-05	0.00114	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—systemic lupus erythematosus	4.49e-05	0.00114	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	4.48e-05	0.00113	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—systemic lupus erythematosus	4.48e-05	0.00113	CcSEcCtD
Crizotinib—ABCB1—blood plasma—systemic lupus erythematosus	4.44e-05	0.000833	CbGeAlD
Crizotinib—Dyspepsia—Triamcinolone—systemic lupus erythematosus	4.43e-05	0.00112	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	4.42e-05	0.00112	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—systemic lupus erythematosus	4.37e-05	0.00111	CcSEcCtD
Crizotinib—Syncope—Prednisone—systemic lupus erythematosus	4.37e-05	0.00111	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—systemic lupus erythematosus	4.34e-05	0.0011	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—systemic lupus erythematosus	4.34e-05	0.0011	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—systemic lupus erythematosus	4.33e-05	0.0011	CcSEcCtD
Crizotinib—Asthenia—Cyclosporine—systemic lupus erythematosus	4.32e-05	0.00109	CcSEcCtD
Crizotinib—CYP3A5—nephron tubule—systemic lupus erythematosus	4.31e-05	0.000809	CbGeAlD
Crizotinib—Loss of consciousness—Prednisone—systemic lupus erythematosus	4.29e-05	0.00108	CcSEcCtD
Crizotinib—ABL1—nervous system—systemic lupus erythematosus	4.25e-05	0.000797	CbGeAlD
Crizotinib—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	4.23e-05	0.00107	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	4.22e-05	0.00107	CcSEcCtD
Crizotinib—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	4.21e-05	0.00107	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	4.12e-05	0.00104	CcSEcCtD
Crizotinib—Diarrhoea—Cyclosporine—systemic lupus erythematosus	4.12e-05	0.00104	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—systemic lupus erythematosus	4.1e-05	0.00104	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—systemic lupus erythematosus	4.1e-05	0.00104	CcSEcCtD
Crizotinib—ABL1—central nervous system—systemic lupus erythematosus	4.09e-05	0.000767	CbGeAlD
Crizotinib—Malnutrition—Methotrexate—systemic lupus erythematosus	4.07e-05	0.00103	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—systemic lupus erythematosus	4.02e-05	0.00102	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—systemic lupus erythematosus	4.02e-05	0.00102	CcSEcCtD
Crizotinib—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	4.02e-05	0.00102	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—systemic lupus erythematosus	3.99e-05	0.00101	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—systemic lupus erythematosus	3.98e-05	0.00101	CcSEcCtD
Crizotinib—Dizziness—Cyclosporine—systemic lupus erythematosus	3.98e-05	0.00101	CcSEcCtD
Crizotinib—Oedema—Prednisone—systemic lupus erythematosus	3.98e-05	0.00101	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—systemic lupus erythematosus	3.97e-05	0.001	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—systemic lupus erythematosus	3.97e-05	0.001	CcSEcCtD
Crizotinib—Infection—Prednisone—systemic lupus erythematosus	3.95e-05	0.001	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	3.95e-05	0.000998	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	3.95e-05	0.000998	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—systemic lupus erythematosus	3.94e-05	0.000996	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—systemic lupus erythematosus	3.94e-05	0.000996	CcSEcCtD
Crizotinib—Shock—Prednisone—systemic lupus erythematosus	3.92e-05	0.00099	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—systemic lupus erythematosus	3.9e-05	0.000987	CcSEcCtD
Crizotinib—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	3.88e-05	0.000982	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—systemic lupus erythematosus	3.87e-05	0.000977	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—systemic lupus erythematosus	3.84e-05	0.000971	CcSEcCtD
Crizotinib—Asthenia—Hydrocortisone—systemic lupus erythematosus	3.84e-05	0.00097	CcSEcCtD
Crizotinib—Vomiting—Cyclosporine—systemic lupus erythematosus	3.83e-05	0.000968	CcSEcCtD
Crizotinib—Rash—Cyclosporine—systemic lupus erythematosus	3.79e-05	0.000959	CcSEcCtD
Crizotinib—CYP3A5—kidney—systemic lupus erythematosus	3.79e-05	0.000711	CbGeAlD
Crizotinib—Dermatitis—Cyclosporine—systemic lupus erythematosus	3.79e-05	0.000959	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—systemic lupus erythematosus	3.77e-05	0.000952	CcSEcCtD
Crizotinib—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	3.73e-05	0.000944	CcSEcCtD
Crizotinib—Rash—Mycophenolate mofetil—systemic lupus erythematosus	3.7e-05	0.000936	CcSEcCtD
Crizotinib—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	3.7e-05	0.000935	CcSEcCtD
Crizotinib—CYP3A5—cortex of kidney—systemic lupus erythematosus	3.69e-05	0.000693	CbGeAlD
Crizotinib—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	3.66e-05	0.000925	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—systemic lupus erythematosus	3.65e-05	0.000922	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—systemic lupus erythematosus	3.62e-05	0.000916	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—systemic lupus erythematosus	3.61e-05	0.000914	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—systemic lupus erythematosus	3.61e-05	0.000913	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—systemic lupus erythematosus	3.61e-05	0.000913	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—systemic lupus erythematosus	3.61e-05	0.000912	CcSEcCtD
Crizotinib—Nausea—Cyclosporine—systemic lupus erythematosus	3.57e-05	0.000904	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—systemic lupus erythematosus	3.57e-05	0.000904	CcSEcCtD
Crizotinib—Dizziness—Hydrocortisone—systemic lupus erythematosus	3.54e-05	0.000894	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—systemic lupus erythematosus	3.5e-05	0.000886	CcSEcCtD
Crizotinib—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	3.49e-05	0.000882	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—systemic lupus erythematosus	3.46e-05	0.000875	CcSEcCtD
Crizotinib—Rash—Prednisolone—systemic lupus erythematosus	3.45e-05	0.000873	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—systemic lupus erythematosus	3.45e-05	0.000872	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	3.45e-05	0.000871	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	3.44e-05	0.000869	CcSEcCtD
Crizotinib—Fatigue—Prednisone—systemic lupus erythematosus	3.43e-05	0.000868	CcSEcCtD
Crizotinib—Constipation—Prednisone—systemic lupus erythematosus	3.4e-05	0.00086	CcSEcCtD
Crizotinib—Vomiting—Hydrocortisone—systemic lupus erythematosus	3.4e-05	0.00086	CcSEcCtD
Crizotinib—Rash—Hydrocortisone—systemic lupus erythematosus	3.37e-05	0.000853	CcSEcCtD
Crizotinib—Dermatitis—Hydrocortisone—systemic lupus erythematosus	3.37e-05	0.000852	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—systemic lupus erythematosus	3.33e-05	0.000842	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—systemic lupus erythematosus	3.32e-05	0.00084	CcSEcCtD
Crizotinib—Infection—Methotrexate—systemic lupus erythematosus	3.3e-05	0.000835	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—systemic lupus erythematosus	3.28e-05	0.000829	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—systemic lupus erythematosus	3.28e-05	0.000829	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—systemic lupus erythematosus	3.26e-05	0.000825	CcSEcCtD
Crizotinib—Nausea—Prednisolone—systemic lupus erythematosus	3.25e-05	0.000822	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—systemic lupus erythematosus	3.23e-05	0.000817	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—systemic lupus erythematosus	3.2e-05	0.00081	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—systemic lupus erythematosus	3.19e-05	0.000808	CcSEcCtD
Crizotinib—Nausea—Hydrocortisone—systemic lupus erythematosus	3.18e-05	0.000803	CcSEcCtD
Crizotinib—Rash—Triamcinolone—systemic lupus erythematosus	3.18e-05	0.000803	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—systemic lupus erythematosus	3.17e-05	0.000802	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—systemic lupus erythematosus	3.17e-05	0.000801	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—systemic lupus erythematosus	3.17e-05	0.0008	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—systemic lupus erythematosus	3.15e-05	0.000795	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—systemic lupus erythematosus	3.13e-05	0.000791	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—systemic lupus erythematosus	3.13e-05	0.000791	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Hydrocortisone—systemic lupus erythematosus	3.1e-05	0.0187	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Hydrocortisone—systemic lupus erythematosus	3.1e-05	0.0187	CbGdCrCtD
Crizotinib—Dizziness—Betamethasone—systemic lupus erythematosus	3.02e-05	0.000764	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—systemic lupus erythematosus	3.02e-05	0.000764	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—systemic lupus erythematosus	2.99e-05	0.000756	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—systemic lupus erythematosus	2.99e-05	0.000755	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—systemic lupus erythematosus	2.98e-05	0.000755	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—systemic lupus erythematosus	2.97e-05	0.00075	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—systemic lupus erythematosus	2.93e-05	0.00074	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—systemic lupus erythematosus	2.93e-05	0.0177	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—systemic lupus erythematosus	2.93e-05	0.0177	CbGdCrCtD
Crizotinib—Vomiting—Betamethasone—systemic lupus erythematosus	2.91e-05	0.000735	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—systemic lupus erythematosus	2.91e-05	0.000735	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000731	CcSEcCtD
Crizotinib—Rash—Dexamethasone—systemic lupus erythematosus	2.88e-05	0.000729	CcSEcCtD
Crizotinib—Rash—Betamethasone—systemic lupus erythematosus	2.88e-05	0.000729	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—systemic lupus erythematosus	2.88e-05	0.0174	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—systemic lupus erythematosus	2.88e-05	0.0174	CbGdCrCtD
Crizotinib—Dermatitis—Betamethasone—systemic lupus erythematosus	2.88e-05	0.000728	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—systemic lupus erythematosus	2.88e-05	0.000728	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	2.87e-05	0.000726	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—systemic lupus erythematosus	2.87e-05	0.000725	CcSEcCtD
Crizotinib—Asthenia—Prednisone—systemic lupus erythematosus	2.86e-05	0.000722	CcSEcCtD
Crizotinib—CYP3A4—kidney—systemic lupus erythematosus	2.84e-05	0.000534	CbGeAlD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—systemic lupus erythematosus	2.81e-05	0.017	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—systemic lupus erythematosus	2.81e-05	0.017	CbGdCrCtD
Crizotinib—Diarrhoea—Prednisone—systemic lupus erythematosus	2.72e-05	0.000688	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—systemic lupus erythematosus	2.71e-05	0.000686	CcSEcCtD
Crizotinib—Nausea—Betamethasone—systemic lupus erythematosus	2.71e-05	0.000686	CcSEcCtD
Crizotinib—CYP3A5—lung—systemic lupus erythematosus	2.69e-05	0.000504	CbGeAlD
Crizotinib—ACVR1—Dexamethasone—Prednisone—systemic lupus erythematosus	2.67e-05	0.0161	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—systemic lupus erythematosus	2.67e-05	0.0161	CbGdCrCtD
Crizotinib—Dizziness—Prednisone—systemic lupus erythematosus	2.63e-05	0.000665	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—systemic lupus erythematosus	2.63e-05	0.000665	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—systemic lupus erythematosus	2.61e-05	0.0158	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—systemic lupus erythematosus	2.61e-05	0.0158	CbGdCrCtD
Crizotinib—Vomiting—Prednisone—systemic lupus erythematosus	2.53e-05	0.00064	CcSEcCtD
Crizotinib—Rash—Prednisone—systemic lupus erythematosus	2.51e-05	0.000634	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—systemic lupus erythematosus	2.51e-05	0.000634	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—systemic lupus erythematosus	2.39e-05	0.000603	CcSEcCtD
Crizotinib—Nausea—Prednisone—systemic lupus erythematosus	2.36e-05	0.000598	CcSEcCtD
Crizotinib—ABCB1—nephron tubule—systemic lupus erythematosus	2.29e-05	0.00043	CbGeAlD
Crizotinib—Diarrhoea—Methotrexate—systemic lupus erythematosus	2.28e-05	0.000575	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—systemic lupus erythematosus	2.2e-05	0.000556	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—systemic lupus erythematosus	2.11e-05	0.000535	CcSEcCtD
Crizotinib—Rash—Methotrexate—systemic lupus erythematosus	2.1e-05	0.00053	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—systemic lupus erythematosus	2.09e-05	0.00053	CcSEcCtD
Crizotinib—ABCB1—kidney—systemic lupus erythematosus	2.01e-05	0.000378	CbGeAlD
Crizotinib—TESK1—Dexamethasone—Hydrocortisone—systemic lupus erythematosus	2e-05	0.0121	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Hydrocortisone—systemic lupus erythematosus	2e-05	0.0121	CbGdCrCtD
Crizotinib—Nausea—Methotrexate—systemic lupus erythematosus	1.98e-05	0.000499	CcSEcCtD
Crizotinib—ABCB1—cortex of kidney—systemic lupus erythematosus	1.96e-05	0.000368	CbGeAlD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—systemic lupus erythematosus	1.89e-05	0.0114	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—systemic lupus erythematosus	1.89e-05	0.0114	CbGdCrCtD
Crizotinib—CYP3A4—nervous system—systemic lupus erythematosus	1.87e-05	0.00035	CbGeAlD
Crizotinib—TESK1—Dexamethasone—Betamethasone—systemic lupus erythematosus	1.86e-05	0.0112	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—systemic lupus erythematosus	1.86e-05	0.0112	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—systemic lupus erythematosus	1.81e-05	0.011	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—systemic lupus erythematosus	1.81e-05	0.011	CbGdCrCtD
Crizotinib—CYP3A4—central nervous system—systemic lupus erythematosus	1.8e-05	0.000337	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—systemic lupus erythematosus	1.73e-05	0.000324	CbGeAlD
Crizotinib—TESK1—Betamethasone—Prednisone—systemic lupus erythematosus	1.72e-05	0.0104	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—systemic lupus erythematosus	1.72e-05	0.0104	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—systemic lupus erythematosus	1.68e-05	0.0102	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—systemic lupus erythematosus	1.68e-05	0.0102	CbGdCrCtD
Crizotinib—ABCB1—bone marrow—systemic lupus erythematosus	1.58e-05	0.000295	CbGeAlD
Crizotinib—ABCB1—lung—systemic lupus erythematosus	1.43e-05	0.000268	CbGeAlD
Crizotinib—ABCB1—nervous system—systemic lupus erythematosus	1.32e-05	0.000248	CbGeAlD
Crizotinib—ABCB1—central nervous system—systemic lupus erythematosus	1.27e-05	0.000239	CbGeAlD
Crizotinib—SRC—Developmental Biology—TGFB1—systemic lupus erythematosus	6.37e-07	7.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—C3—systemic lupus erythematosus	6.33e-07	7.32e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL2—systemic lupus erythematosus	6.3e-07	7.28e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—systemic lupus erythematosus	6.29e-07	7.27e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—systemic lupus erythematosus	6.26e-07	7.24e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	6.25e-07	7.23e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—systemic lupus erythematosus	6.25e-07	7.22e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD80—systemic lupus erythematosus	6.24e-07	7.21e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—CDKN1A—systemic lupus erythematosus	6.23e-07	7.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRL—systemic lupus erythematosus	6.2e-07	7.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—systemic lupus erythematosus	6.19e-07	7.16e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—systemic lupus erythematosus	6.19e-07	7.15e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—systemic lupus erythematosus	6.14e-07	7.1e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—systemic lupus erythematosus	6.12e-07	7.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TYK2—systemic lupus erythematosus	6.12e-07	7.07e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	6.12e-07	7.07e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL2—systemic lupus erythematosus	6.12e-07	7.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—systemic lupus erythematosus	6.1e-07	7.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR5—systemic lupus erythematosus	6.06e-07	7.01e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	6.06e-07	7.01e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—systemic lupus erythematosus	6.05e-07	6.99e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TYK2—systemic lupus erythematosus	6.03e-07	6.97e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CDKN1A—systemic lupus erythematosus	6.03e-07	6.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TYK2—systemic lupus erythematosus	6.01e-07	6.95e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—systemic lupus erythematosus	6.01e-07	6.94e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD80—systemic lupus erythematosus	5.98e-07	6.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2RA—systemic lupus erythematosus	5.98e-07	6.91e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—systemic lupus erythematosus	5.95e-07	6.88e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—systemic lupus erythematosus	5.93e-07	6.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—systemic lupus erythematosus	5.93e-07	6.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—C3—systemic lupus erythematosus	5.93e-07	6.85e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—systemic lupus erythematosus	5.92e-07	6.85e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—systemic lupus erythematosus	5.92e-07	6.84e-06	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—systemic lupus erythematosus	5.92e-07	6.84e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1B—systemic lupus erythematosus	5.92e-07	6.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—systemic lupus erythematosus	5.9e-07	6.82e-06	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—systemic lupus erythematosus	5.9e-07	6.82e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—systemic lupus erythematosus	5.89e-07	6.81e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1B—systemic lupus erythematosus	5.89e-07	6.81e-06	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—systemic lupus erythematosus	5.84e-07	6.75e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—systemic lupus erythematosus	5.82e-07	6.73e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—systemic lupus erythematosus	5.82e-07	6.72e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—systemic lupus erythematosus	5.81e-07	6.72e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—systemic lupus erythematosus	5.79e-07	6.69e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—systemic lupus erythematosus	5.79e-07	6.69e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—systemic lupus erythematosus	5.79e-07	6.69e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	5.77e-07	6.67e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—systemic lupus erythematosus	5.76e-07	6.66e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—systemic lupus erythematosus	5.74e-07	6.63e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TYK2—systemic lupus erythematosus	5.72e-07	6.61e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—systemic lupus erythematosus	5.71e-07	6.6e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—TYK2—systemic lupus erythematosus	5.7e-07	6.59e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—systemic lupus erythematosus	5.68e-07	6.56e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—systemic lupus erythematosus	5.67e-07	6.56e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—systemic lupus erythematosus	5.65e-07	6.53e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—systemic lupus erythematosus	5.62e-07	6.49e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—systemic lupus erythematosus	5.62e-07	6.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JAK1—systemic lupus erythematosus	5.6e-07	6.48e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	5.6e-07	6.47e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—F2—systemic lupus erythematosus	5.56e-07	6.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1B—systemic lupus erythematosus	5.54e-07	6.4e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—RXRA—systemic lupus erythematosus	5.53e-07	6.39e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD80—systemic lupus erythematosus	5.52e-07	6.38e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—systemic lupus erythematosus	5.51e-07	6.37e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—systemic lupus erythematosus	5.49e-07	6.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—systemic lupus erythematosus	5.47e-07	6.32e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1A—systemic lupus erythematosus	5.46e-07	6.31e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—systemic lupus erythematosus	5.45e-07	6.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—systemic lupus erythematosus	5.44e-07	6.28e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1A—systemic lupus erythematosus	5.44e-07	6.28e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—systemic lupus erythematosus	5.43e-07	6.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—systemic lupus erythematosus	5.42e-07	6.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—systemic lupus erythematosus	5.4e-07	6.24e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—systemic lupus erythematosus	5.34e-07	6.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CD80—systemic lupus erythematosus	5.33e-07	6.16e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—systemic lupus erythematosus	5.32e-07	6.15e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—systemic lupus erythematosus	5.31e-07	6.14e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TYK2—systemic lupus erythematosus	5.27e-07	6.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2RA—systemic lupus erythematosus	5.23e-07	6.05e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1B—systemic lupus erythematosus	5.2e-07	6.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—F2—systemic lupus erythematosus	5.2e-07	6.01e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—systemic lupus erythematosus	5.2e-07	6.01e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—systemic lupus erythematosus	5.2e-07	6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—C3—systemic lupus erythematosus	5.19e-07	6e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—systemic lupus erythematosus	5.17e-07	5.98e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—systemic lupus erythematosus	5.17e-07	5.97e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—systemic lupus erythematosus	5.16e-07	5.96e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—systemic lupus erythematosus	5.15e-07	5.95e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	5.13e-07	5.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1B—systemic lupus erythematosus	5.11e-07	5.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1A—systemic lupus erythematosus	5.11e-07	5.91e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—systemic lupus erythematosus	5.09e-07	5.88e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	5.06e-07	5.85e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—systemic lupus erythematosus	5.06e-07	5.85e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—TYK2—systemic lupus erythematosus	5.05e-07	5.84e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—systemic lupus erythematosus	5.04e-07	5.83e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—systemic lupus erythematosus	5.02e-07	5.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CD80—systemic lupus erythematosus	4.99e-07	5.76e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—systemic lupus erythematosus	4.99e-07	5.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JAK1—systemic lupus erythematosus	4.96e-07	5.73e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—systemic lupus erythematosus	4.95e-07	5.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	4.87e-07	5.62e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—systemic lupus erythematosus	4.86e-07	5.62e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1B—systemic lupus erythematosus	4.85e-07	5.6e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—systemic lupus erythematosus	4.82e-07	5.57e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—systemic lupus erythematosus	4.8e-07	5.55e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.8e-07	5.55e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—systemic lupus erythematosus	4.79e-07	5.54e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—systemic lupus erythematosus	4.77e-07	5.52e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—systemic lupus erythematosus	4.76e-07	5.5e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—systemic lupus erythematosus	4.76e-07	5.5e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—systemic lupus erythematosus	4.75e-07	5.49e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—systemic lupus erythematosus	4.75e-07	5.48e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.73e-07	5.47e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—systemic lupus erythematosus	4.73e-07	5.46e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—systemic lupus erythematosus	4.73e-07	5.46e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1B—systemic lupus erythematosus	4.72e-07	5.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1A—systemic lupus erythematosus	4.72e-07	5.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—systemic lupus erythematosus	4.7e-07	5.43e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TYK2—systemic lupus erythematosus	4.66e-07	5.39e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—systemic lupus erythematosus	4.64e-07	5.36e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2RA—systemic lupus erythematosus	4.63e-07	5.35e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—systemic lupus erythematosus	4.63e-07	5.35e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—systemic lupus erythematosus	4.63e-07	5.35e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—systemic lupus erythematosus	4.62e-07	5.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—systemic lupus erythematosus	4.6e-07	5.32e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—C3—systemic lupus erythematosus	4.59e-07	5.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	4.59e-07	5.3e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—systemic lupus erythematosus	4.58e-07	5.29e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—systemic lupus erythematosus	4.57e-07	5.28e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—systemic lupus erythematosus	4.57e-07	5.28e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—systemic lupus erythematosus	4.56e-07	5.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—F2—systemic lupus erythematosus	4.56e-07	5.27e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—systemic lupus erythematosus	4.51e-07	5.21e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—systemic lupus erythematosus	4.51e-07	5.21e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TYK2—systemic lupus erythematosus	4.5e-07	5.2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.49e-07	5.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—systemic lupus erythematosus	4.49e-07	5.19e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1B—systemic lupus erythematosus	4.48e-07	5.17e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1A—systemic lupus erythematosus	4.48e-07	5.17e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—systemic lupus erythematosus	4.42e-07	5.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—systemic lupus erythematosus	4.38e-07	5.06e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD80—systemic lupus erythematosus	4.37e-07	5.05e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.36e-07	5.04e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—systemic lupus erythematosus	4.33e-07	5e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.33e-07	5e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1B—systemic lupus erythematosus	4.29e-07	4.96e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—systemic lupus erythematosus	4.28e-07	4.94e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—systemic lupus erythematosus	4.27e-07	4.94e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.27e-07	4.93e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—systemic lupus erythematosus	4.26e-07	4.92e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—systemic lupus erythematosus	4.24e-07	4.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—systemic lupus erythematosus	4.22e-07	4.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TYK2—systemic lupus erythematosus	4.21e-07	4.87e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—systemic lupus erythematosus	4.2e-07	4.86e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—systemic lupus erythematosus	4.2e-07	4.86e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—systemic lupus erythematosus	4.19e-07	4.84e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	4.18e-07	4.82e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—systemic lupus erythematosus	4.15e-07	4.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—systemic lupus erythematosus	4.13e-07	4.78e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—systemic lupus erythematosus	4.13e-07	4.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—systemic lupus erythematosus	4.06e-07	4.69e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.05e-07	4.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—F2—systemic lupus erythematosus	4.03e-07	4.66e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.97e-07	4.59e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—systemic lupus erythematosus	3.96e-07	4.58e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—systemic lupus erythematosus	3.96e-07	4.58e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—systemic lupus erythematosus	3.93e-07	4.54e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—systemic lupus erythematosus	3.93e-07	4.54e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.92e-07	4.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—systemic lupus erythematosus	3.9e-07	4.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—systemic lupus erythematosus	3.88e-07	4.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD80—systemic lupus erythematosus	3.87e-07	4.47e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.83e-07	4.42e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—systemic lupus erythematosus	3.81e-07	4.41e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—systemic lupus erythematosus	3.77e-07	4.36e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—systemic lupus erythematosus	3.76e-07	4.34e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—systemic lupus erythematosus	3.74e-07	4.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.71e-07	4.29e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—systemic lupus erythematosus	3.69e-07	4.26e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—systemic lupus erythematosus	3.66e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—systemic lupus erythematosus	3.62e-07	4.18e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.61e-07	4.17e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—systemic lupus erythematosus	3.6e-07	4.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—systemic lupus erythematosus	3.6e-07	4.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.58e-07	4.14e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—systemic lupus erythematosus	3.54e-07	4.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.53e-07	4.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—systemic lupus erythematosus	3.5e-07	4.05e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—systemic lupus erythematosus	3.49e-07	4.04e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—systemic lupus erythematosus	3.49e-07	4.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—systemic lupus erythematosus	3.49e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—systemic lupus erythematosus	3.48e-07	4.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—systemic lupus erythematosus	3.42e-07	3.95e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—systemic lupus erythematosus	3.4e-07	3.93e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—systemic lupus erythematosus	3.39e-07	3.91e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—systemic lupus erythematosus	3.36e-07	3.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—systemic lupus erythematosus	3.32e-07	3.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.3e-07	3.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—systemic lupus erythematosus	3.26e-07	3.77e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—systemic lupus erythematosus	3.2e-07	3.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—systemic lupus erythematosus	3.19e-07	3.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—systemic lupus erythematosus	3.18e-07	3.68e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—systemic lupus erythematosus	3.14e-07	3.63e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—systemic lupus erythematosus	3.14e-07	3.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.14e-07	3.62e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—systemic lupus erythematosus	3.07e-07	3.55e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—systemic lupus erythematosus	3.03e-07	3.5e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—systemic lupus erythematosus	3e-07	3.47e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—systemic lupus erythematosus	2.99e-07	3.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.98e-07	3.44e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—systemic lupus erythematosus	2.95e-07	3.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—systemic lupus erythematosus	2.94e-07	3.4e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.92e-07	3.37e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—systemic lupus erythematosus	2.9e-07	3.36e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.89e-07	3.34e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—systemic lupus erythematosus	2.8e-07	3.23e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—systemic lupus erythematosus	2.79e-07	3.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.78e-07	3.21e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—systemic lupus erythematosus	2.75e-07	3.18e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—systemic lupus erythematosus	2.75e-07	3.18e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.73e-07	3.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—systemic lupus erythematosus	2.72e-07	3.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—systemic lupus erythematosus	2.72e-07	3.14e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	2.64e-07	3.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.61e-07	3.01e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—systemic lupus erythematosus	2.58e-07	2.98e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	2.57e-07	2.97e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—systemic lupus erythematosus	2.57e-07	2.97e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.56e-07	2.96e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—systemic lupus erythematosus	2.47e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—systemic lupus erythematosus	2.44e-07	2.82e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.39e-07	2.77e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—systemic lupus erythematosus	2.37e-07	2.74e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.31e-07	2.67e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—systemic lupus erythematosus	2.29e-07	2.64e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—systemic lupus erythematosus	2.28e-07	2.64e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	2.27e-07	2.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—systemic lupus erythematosus	2.2e-07	2.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.12e-07	2.45e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	2.07e-07	2.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—systemic lupus erythematosus	2.06e-07	2.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—systemic lupus erythematosus	1.8e-07	2.08e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—systemic lupus erythematosus	1.72e-07	1.99e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	1.62e-07	1.88e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—systemic lupus erythematosus	1.6e-07	1.85e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	1.46e-07	1.69e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	1.4e-07	1.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	1.28e-07	1.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	1.06e-07	1.23e-06	CbGpPWpGaD
